Loading clinical trials...
Loading clinical trials...
A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)
Conditions
Interventions
LMB763
Placebo
Locations
30
United States
Novartis Investigative Site
Culver City, California, United States
Novartis Investigative Site
Cypress, California, United States
Novartis Investigative Site
Gainesville, Florida, United States
Novartis Investigative Site
Miami Springs, Florida, United States
Novartis Investigative Site
Orlando, Florida, United States
Novartis Investigative Site
Orlando, Florida, United States
Start Date
October 24, 2016
Primary Completion Date
September 19, 2018
Completion Date
September 19, 2018
Last Updated
January 5, 2021
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions